Retina/Vitreous News

ATHENS, Greece — Retinal re-detachment following cataract extraction remains significant in patients who have previously undergone pars plana vitrectomy for retinal detachment, according to a study.

  The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, according to a press release from ANI Pharmaceuticals.

Altris AI, which offers OCT analysis for retinal diseases, is now expanding to glaucoma detection.

  The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

  The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at Angiogenesis, Exudation, and Degeneration 2025.

Geographic atrophy lesion location may be a critical factor in vision-related quality of life, according to a presentation at Angiogenesis, Exudation, and Degeneration 2025.

ORLANDO — In this Healio Video Perspective from Telling It Like It Is, Jaclyn L. Kovach, MD, FASRS, overviews systemic therapies and retinal toxicity.

Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by bias, data quality and limited generalizability, according to a review published in BMJ Open Ophthalmology.